ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

Rhea-AI Summary

ORIC Pharmaceuticals, a clinical-stage oncology company, announced participation in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 2:00 p.m. ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 90 days post-event.

ORIC focuses on developing treatments that address mechanisms of therapeutic resistance, with product candidates including ORIC-533 for multiple myeloma, ORIC-114 targeting genetically defined cancers, and ORIC-944 for prostate cancer. The company operates from South San Francisco and San Diego, California.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET.

The live webcast of the discussion will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

When will ORIC Pharmaceuticals participate in the H.C. Wainwright BioConnect Investor Conference?

ORIC Pharmaceuticals will participate in the conference on May 2, 2023, at 2:00 p.m. ET.

How can I watch the ORIC Pharmaceuticals fireside chat live?

You can watch the live webcast of the ORIC Pharmaceuticals fireside chat through the investor section of their website.

What are the key product candidates being developed by ORIC Pharmaceuticals?

ORIC Pharmaceuticals is developing ORIC-533 for multiple myeloma, ORIC-114 for genetically defined cancers, and ORIC-944 for prostate cancer.

How long will the replay of the ORIC Pharmaceuticals webcast be available?

The replay of the webcast will be available for 90 days after the event.

What is ORIC Pharmaceuticals' main focus?

ORIC Pharmaceuticals primarily focuses on developing treatments that address mechanisms of therapeutic resistance in cancer.